Literature DB >> 35892315

Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Alberto Guijosa1, Ana Freyria1, Jose Rodrigo Espinosa-Fernandez2, Francisco J Estrada-Mena1, Ana Sofía Armenta-Quiroga1, Maria Fernanda Ortega-Treviño1, Rodrigo Catalán1,3, Bani Antonio-Aguirre4, Cynthia Villarreal-Garza5, Andric C Perez-Ortiz1,6.   

Abstract

Taxane-based chemotherapy regimens are used as first-line treatment for breast cancer. Neurotoxicity, mainly taxane-induced peripheral neuropathy (TIPN), remains the most important dose-limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the association remain unclear. For this reason, we systematically reviewed observational studies of TIPN pharmacogenetic markers in breast cancer treatment. We conducted a systematic search of terms alluding to breast cancer, genetic markers, taxanes, and neurotoxicity in Ovid, ProQuest, PubMed, Scopus, Virtual Health, and Web of Science. We assessed the quality of evidence and bias profile. We extracted relevant variables and effect measures. Whenever possible, we performed random-effects gene meta-analyses and examined interstudy heterogeneity with meta-regression models and subgroup analyses. This study follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidance. A total of 42 studies with 19,431 participants were included. These evaluated 262 single-nucleotide polymorphisms (SNPs) across 121 genes. We conducted meta-analyses on 23 genes with 60 SNPs (19 studies and 6246 participants). Thirteen individual SNPs (ABCB1-rs2032582, ABCB1-rs3213619, BCL6/-rs1903216, /CAND1-rs17781082, CYP1B1-rs1056836, CYP2C8-rs10509681, CYP2C8-rs11572080, EPHA5-rs7349683, EPHA6-rs301927, FZD3-rs7001034, GSTP1-rs1138272, TUBB2A-rs9501929, and XKR4-rs4737264) and the overall SNPs' effect in four genes (CYP3A4, EphA5, GSTP1, and SLCO1B1) were statistically significantly associated with TIPN through meta-analysis. In conclusion, through systematic review and meta-analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making.
© 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35892315      PMCID: PMC9579387          DOI: 10.1111/cts.13370

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.438


  96 in total

1.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Sara M Tolaney; Hao Guo; Sonia Pernas; William T Barry; Deborah A Dillon; Lauren Ritterhouse; Bryan P Schneider; Fei Shen; Kit Fuhrman; Michele Baltay; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Mathew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth Overmoyer; Ann H Partridge; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

Review 2.  Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.

Authors:  Andreas A Argyriou; Jordi Bruna; Armando A Genazzani; Guido Cavaletti
Journal:  Nat Rev Neurol       Date:  2017-06-30       Impact factor: 42.937

3.  Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Authors:  Lara E Sucheston-Campbell; Alyssa I Clay-Gilmour; William E Barlow; G Thomas Budd; Daniel O Stram; Christopher A Haiman; Xin Sheng; Li Yan; Gary Zirpoli; Song Yao; Chen Jiang; Kouros Owzar; Dawn Hershman; Kathy S Albain; Daniel F Hayes; Halle C Moore; Timothy J Hobday; James A Stewart; Abbas Rizvi; Claudine Isaacs; Muhammad Salim; Jule R Gralow; Gabriel N Hortobagyi; Robert B Livingston; Deanna L Kroetz; Christine B Ambrosone
Journal:  Pharmacogenet Genomics       Date:  2018-02       Impact factor: 2.089

4.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

5.  Taxane pathway.

Authors:  Connie Oshiro; Sharon Marsh; Howard McLeod; Michelle Whirl Carrillo; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

6.  SNPs and taxane toxicity in breast cancer patients.

Authors:  Virginia Bosó; María José Herrero; Ana Santaballa; Laura Palomar; Juan E Megias; Helena de la Cueva; Luis Rojas; María Remedios Marqués; José Luis Poveda; Joaquin Montalar; Salvador F Aliño
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

7.  Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.

Authors:  Luis J Leandro-García; Lucía Inglada-Pérez; Guillermo Pita; Elisabet Hjerpe; Susanna Leskelä; Carlos Jara; Xabier Mielgo; Anna González-Neira; Mercedes Robledo; Elisabeth Avall-Lundqvist; Henrik Gréen; Cristina Rodríguez-Antona
Journal:  J Med Genet       Date:  2013-06-17       Impact factor: 6.318

8.  Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.

Authors:  H Chang; S Y Rha; H-C Jeung; C-K Im; J B Ahn; W S Kwon; N C Yoo; J K Roh; H C Chung
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

9.  Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins.

Authors:  F Ali-Osman; O Akande; G Antoun; J X Mao; J Buolamwini
Journal:  J Biol Chem       Date:  1997-04-11       Impact factor: 5.157

10.  Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.

Authors:  Lauren A Marcath; Kelley M Kidwell; Kiran Vangipuram; Christina L Gersch; James M Rae; Monika L Burness; Jennifer J Griggs; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry; Andreas S Beutler; Daniel L Hertz
Journal:  Br J Clin Pharmacol       Date:  2020-02-04       Impact factor: 4.335

View more
  1 in total

1.  Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Authors:  Alberto Guijosa; Ana Freyria; Jose Rodrigo Espinosa-Fernandez; Francisco J Estrada-Mena; Ana Sofía Armenta-Quiroga; Maria Fernanda Ortega-Treviño; Rodrigo Catalán; Bani Antonio-Aguirre; Cynthia Villarreal-Garza; Andric C Perez-Ortiz
Journal:  Clin Transl Sci       Date:  2022-08-17       Impact factor: 4.438

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.